可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Kjaer A, Hesse B. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives[J]. Clin Physiol, 2001,21(6):661-672.
[2] Maisel AS, Koon J, Krishnaswamy P, et al. Utility of Btype natriuretic peptide as a rapid, point of care test for screening patients undergoing echocardiongraphy to determine left ventricular dys function[J]. Am Heart J, 2001,141(3):367-374.
[3] Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting[J]. J Am Coll Cardiol, 2001,37(2):379-385.
[4] Dahlof B,Devereux RB,Kjeldsen SE,et al.Cardiovascular morbidity and mortality in the lorsartan intervention for endpoint reduction in hypertention study (LIFE): a randomized trial against atenolol[J]. Lancet, 2002,359(9311):995-1003.